Dalteparin sodium 7,500units/0.3ml solution for injection pre-filled syringes
Requires a prescription from a doctor or prescriber
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Dalteparin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Dalteparin on the MHRA register
Fragmin 7,500units/0.3ml solution for injection pre-filled syringes
Dalteparin sodium 7,500units/0.3ml solution for injection pre-filled syringes
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
2500 unit
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
Diabetic foot problems: prevention and management (NG19)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 16 · 1995–2026
Showing the 50 most relevant studies, sorted by most relevant.
Alain Leizorovicz, Alexander T Cohen, Alexander G.G. Turpie, et al.
Circulation, 2004
- Acute Disease
- Anticoagulants
- Death, Sudden
Giancarlo Agnelli, David Bergqvist, Alexander T. Cohen, et al.
British journal of surgery, 2005
- Abdomen
- Fondaparinux
- Administration, Cutaneous
B. Eriksson, D. Bergqvist, P. Kälebo, et al.
Lancet, 2002
- Anticoagulants
- Azetidines
- Benzylamines
Marc Rodger, William M. Hague, John Kingdom, et al.
The Lancet, 2014
- Fibrinolytic Agents
- Hemorrhage
- Pregnancy Complications, Cardiovascular
James Perry, J.A. Julian, Normand Laperrière, et al.
Journal of Thrombosis and Haemostasis, 2010
- Anticoagulants
- Brain Neoplasms
- Glioma
Évelyne Rey, Pierre Y. Garneau, Matthias David, et al.
Journal of Thrombosis and Haemostasis, 2008
- Fetal Death
- Infant, Low Birth Weight
- Pilot Projects
Alok A. Khorana, Charles W. Francis, Nicole M. Kuderer, et al.
Thrombosis Research, 2017
- Anticoagulants
- Hemorrhage
- Neoplasms
Arce-Huamani MA, Barboza JJ, Martínez-Herrera JF, et al.
2023
- Neoplasms
- Venous Thromboembolism
- Hemorrhage
Rojas-Suarez J, Gutiérrez Clavijo JC, Zakzuk J, et al.
2024
PurposeTo analyze the costs of high thromboembolic risk patients who require low molecular weight heparins (LMWHs) as a thromboprophylaxis strategy.MethodsCost analysis was conducted to assess LMWHs (enoxaparin versus comparators: nadroparin and dalteparin) as thromboprophylaxis for hospitalized patients with high thromboembolic risk in Oncology, General or Orthopedic Surgery, and Internal Medicine services from the healthcare provider's perspective in Colombia. A decision tree was developed, and the health outcomes considered in the analysis were deep vein thrombosis, major bleeding, pulmonary thromboembolism, and chronic pulmonary hypertension. Clinical inputs were obtained from a systematic review of the literature and the economic parameters from micro-costing. Inputs were validated by three clinical experts. Costs were expressed in 2020 US dollars (USD).ResultsIn a hypothetical cohort of 10,000 patients with a thromboprophylaxis use rate of 40%, the use of enoxaparin was less costly than that of dalteparin in Oncology (difference of USD 624,669), Orthopedic Surgery (difference of USD 275,829), and Internal Medicine (difference of USD 109,119) patients. For these services, using enoxaparin was more efficient than using nadroparin (cost differences of USD 654,069, USD 416,927, and USD 92,070, respectively). Sensitivity analysis showed an important influence of the number of patients undergoing thromboprophylaxis, as well as the unit cost, and the risk of events (DVT, PTE, and CTEPH).ConclusionEnoxaparin is the least expensive health technology for thromboprophylaxis in most of the medical contexts analyzed in Colombia due to its efficacy and the lower risk of complications than dalteparin and nadroparin.
Abstract licence: CC BY-NC
Miguel A. Arce-Huamani, Joshuan J. Barboza, José Fabián Martínez-Herrera, et al.
Medicina, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
157 found
Half-life
2 hours
Mechanism
Dalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin.
Food interactions
1 warning
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
87%
Half-life
2 hours
Intravenous - 2 hours. Subcutaneous - 3-5hours
Protein binding
90%
Volume of distribution
Metabolism
Elimination
4 hours
Clearance
33 mL/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein GP IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).
It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 863 interactions
Adverse Drug Reaction:
(common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia.
(uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema
How the body processes this drug — absorption, distribution, metabolism, and elimination
Intravenous - 2 hours. Subcutaneous - 3-5hours
Proteins and enzymes this drug interacts with in the body
PMID:15140129 PMID:15853774
AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa .
PMID:15140129
Its inhibitory activity is greatly enhanced in the presence of heparin
PMID:35455969
Involved in protecting cells from hypoxia-mediated cell death (By similarity)
Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with SELPLG. Mediates cell-cell interactions and cell adhesion via the interaction with integrin alpha-IIb/beta3 (ITGA2B:ITGB3) and integrin alpha-V/beta-3 (ITGAV:ITGB3) PMID:37184585
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC B01AB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Dalteparin
Additional database identifiers
Drugs Product Database (DPD)
269
HUGO Gene Nomenclature Committee (HGNC)
HGNC:775
GenAtlas
SERPINC1
GeneCards
SERPINC1
GenBank Gene Database
M21642
GenBank Protein Database
179161
Guide to Pharmacology
2632
UniProt Accession
ANT3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12680
GenAtlas
VEGF
GeneCards
VEGFA
GenBank Gene Database
M32977
GenBank Protein Database
181971
UniProt Accession
VEGFA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10721
GenAtlas
SELP
GeneCards
SELP
GenBank Gene Database
M60234
GenBank Protein Database
183389
Guide to Pharmacology
3103
UniProt Accession
LYAM3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5164
GenAtlas
HPSE
GeneCards
HPSE
GenBank Gene Database
AF152376
GenBank Protein Database
5616197
Guide to Pharmacology
2996
UniProt Accession
HPSE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q1851701), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.